<DOC>
	<DOCNO>NCT00014989</DOCNO>
	<brief_summary>As many premature infant survive , number infants health problem increase . The rate cerebral palsy ( CP ) extremely premature infant approximately 20 % . Magnesium sulfate , commonly use drug US stop premature labor , may prevent CP . This trial test whether magnesium sulfate give woman labor premature fetus ( 24 31 week 40 ) reduce rate death moderate severe CP child 2 year . The child receive ultrasound brain infant attend three follow-up visit two year ass health development .</brief_summary>
	<brief_title>Beneficial Effects Antenatal Magnesium Sulfate ( BEAM Trial )</brief_title>
	<detailed_description>The prevalence cerebral palsy increase survival rate extremely premature infant improve . Studies suggest apparent association maternal magnesium sulfate administration reduce risk cerebral palsy . Other study suggest possible association magnesium sulfate reduction neonatal cranial ultrasound abnormality may markers subsequent development cerebral palsy . This multicenter trial test whether prophylactic magnesium sulfate give woman , preterm delivery imminent , reduces risk death moderate severe cerebral palsy child . Women present 24.0 31.6 week gestation advance preterm labor premature rupture membrane ( pPROM ) recent exposure magnesium sulfate randomize receive either intravenous magnesium sulfate mask study drug placebo . The study drug administer 6 gram loading dose follow 2 gram/hour infusion ( equivalent rate placebo ) . If 12 hour , delivery occur anticipate , infusion stop . No parenteral tocolytics IV medication may use . Retreatment study medication give time labor recurs delivery anticipate gestational age &gt; 34.0 wks . Standard clinical management therapy maintain study patient . Patients assess sign intolerance study medication maternal data collect hospital discharge . A sample venous blood collect neonatal cranial ultrasound perform . Up three follow-up visit schedule two year certify examiner , mask study group assignment , collect physical neurological data , include modify Gross Motor Function Classification Scale . The Bayley Scales Infant Development also administer . Cranial ultrasound review centrally . The primary outcome composite outcome death moderate severe cerebral palsy . Secondary outcome include maternal infectious morbidity , pulmonary edema placental abruption , neonatal stillbirth death , intraventricular hemorrhage , periventricular leukomalacia , neonatal infectious noninfectious morbidity .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Pulmonary Edema</mesh_term>
	<mesh_term>Leukomalacia , Periventricular</mesh_term>
	<mesh_term>Abruptio Placentae</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>Pregnant diagnosis preterm labor Membrane rupture delivery definitely plan within 24 hour Gestational age &gt; 24.0 &lt; 31.6 wks , viable fetus Prior IV magnesium sulfate therapy within 12 hour screen Delivery expect &lt; 2 hrs Cervical dilation &gt; 8 cm More 2 fetus Known major fetal anomaly Hypertension preeclampsia Maternal medical complication contraindicate magnesium sulfate treatment Participation intervention study influence infant neurological outcome Previous participation trial</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Preterm delivery</keyword>
	<keyword>Cerebral palsy</keyword>
	<keyword>Magnesium sulfate</keyword>
</DOC>